Skip Navigation Menu
Government of Ontario Central Web Site
Ontario Ministry of Health and Long-Term Care
Return to Home Page
Government of Ontario Central Web Site
Contact us for questions and comments
Site map
Version française de cette site web
Information Channels
Public Information
Health Care Providers
News Media
Text Only Version
Index
Health Care Provider Section
Formulary Downloads
O P D P
H O M E
Plan to Reform Ontario’s Drug System
Legislation
Formulary
Publicly Funded Drug Programs
Executive Officer Communications
Drug Submissions
· Ontario Guidelines for Drug
Submission and Evaluation
· Drug Submission Status
· Improving Patient Access to
Drugs: Rapid Review Process
· Single Monthly Formulary
Process
· Off-Formulary
Interchangeability
· Ontario Guidelines for Economic
Analysis of Pharmaceutical
Products
· Submission Guidelines for
Oncology Drugs
· Inter-Provincial Joint
Oncology Drug Review
Process
· Submission Guidelines for
Diabetic Testing Agents
· Submission Guidelines for
Nutrition Products
· Guideline and Template
Downloads
How Drugs Are Approved
Councils
Drug Innovation Fund
(External)
MedsCheck
Glossary
Forms/Guidelines
FAQs
Resources
Contact Us
Ontario Public Drug Programs
Drug Submissions
Drugs funded through Ontario Public Drug Programs are either listed in the Formulary or they are approved through the Exceptional Access program .
The Formulary identifies over 3,200 drug products designated as benefits under the program, as well as drug products that are considered to be interchangeable, and serves as a reimbursement guide for physicians and pharmacists. Drug products listed in the Formulary are designated as General Benefit or Limited Use Drugs .
For drug products to be eligible for listing in the Formulary, a drug manufacturer must provide a complete submission in accordance with the prescribed conditions set out in :
Interpretive guidelines have been published by the Ministry to assist manufacturers in making their submissions.
Each complete submission undergoes a thorough review by the Committee to Evaluate Drugs (CED). Following its review, the CED makes recommendations to the Executive Officer as to whether a drug product should be listed as a Formulary benefit or designated as an interchangeable drug product. As well, CED makes recommendations as to drug products that should be available through the Exceptional Access program. Conditional listing or partnership proposals contained in a drug submission are reviewed by the Ministry, taking into consideration the CED's recommendations. Find out more in the section on how drugs are approved .
This Drug Submission section provides information in the following areas :
For more information
Go to top of page
INFOline
Tel :
1-866-532-3161
(Toll-free in Ontario only)
TTY 1-800-387-5559
Hours of operation: 8:30am - 5:00pm
|
home
| (External)
central site
|
contact us
|
site map
|
français
|
(External)
This site maintained by the government of Ontario, Canada.